menu
    • menu
    [{"orgOrder":0,"company":"Sanwa Kagaku Kenkyusho","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Upacicalcet Sodium","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Sanwa Kagaku Kenkyusho","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanwa Kagaku Kenkyusho \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Sanwa Kagaku Kenkyusho \/ Kissei Pharmaceutical"},{"orgOrder":0,"company":"Pathalys Pharma","sponsor":"DaVita Venture Group","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Upacicalcet Sodium","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Pathalys Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pathalys Pharma \/ DaVita Venture Group","highestDevelopmentStatusID":"12","companyTruncated":"Pathalys Pharma \/ DaVita Venture Group"},{"orgOrder":0,"company":"Pathalys Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Upacicalcet Sodium","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Pathalys Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pathalys Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pathalys Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Pathalys Pharma","sponsor":"Launch Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Upacicalcet Sodium","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Pathalys Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pathalys Pharma \/ Launch Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Pathalys Pharma \/ Launch Therapeutics"},{"orgOrder":0,"company":"Pathalys Pharma","sponsor":"Abingworth","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Upacicalcet Sodium","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Pathalys Pharma","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Pathalys Pharma \/ Abingworth","highestDevelopmentStatusID":"12","companyTruncated":"Pathalys Pharma \/ Abingworth"},{"orgOrder":0,"company":"Pathalys Pharma","sponsor":"Launch Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Upacicalcet Sodium","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Pathalys Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pathalys Pharma \/ Launch Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Pathalys Pharma \/ Launch Therapeutics"},{"orgOrder":0,"company":"Pathalys Pharma","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"Upacicalcet Sodium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Pathalys Pharma","amount2":0.11,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Pathalys Pharma \/ TCGX","highestDevelopmentStatusID":"14","companyTruncated":"Pathalys Pharma \/ TCGX"}]

    Find Clinical Drug Pipeline Developments & Deals for Upacicalcet Sodium

    Menu

    Upacicalcet Sodium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pathalys Pharma

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Pathalys Pharma

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Upacicalcet Sodium

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : TCGX

                            Deal Size : $105.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Pathalys Raises $105M Series B to Prepare Japan-Approved Kidney Disease Drug for FDA

                            Details : The proceeds will fund the two ongoing PLS240 (upacicalcet), a novel calcimimetic, clinical trials, execution of the NDA filing process, and acceleration of preapproval commercialization preparations.

                            Brand Name : Upasita

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 20, 2024

                            Lead Product(s) : Upacicalcet Sodium

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : TCGX

                            Deal Size : $105.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pathalys Pharma

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Pathalys Pharma

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Upacicalcet Sodium

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Launch Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pathalys Pharma and Launch Therapeutics Announce First Patient Enrolled Ahead of Schedule in Pivotal Phase 3 P...

                            Details : Upacicalcet is a novel calcimimetic with the potential to improve the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients. It is already approved in Japan for the treatment of SHPT in patients on dialysis.

                            Brand Name : Upasita

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 31, 2023

                            Lead Product(s) : Upacicalcet Sodium

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Launch Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pathalys Pharma

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Pathalys Pharma

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Upacicalcet Sodium

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Launch Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Pathalys Pharma Raises $150 Million in Secured Product Financing and Equity led by Abingworth; Forms Strategic...

                            Details : Launch Tx will have the lead role in the operational execution and management of the planned clinical trials of Upasita (upacicalcet sodium hydrate) and Pathalys will retain primary responsibility for manufacturing, FDA regulatory interactions and commer...

                            Brand Name : Upasita

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 18, 2023

                            Lead Product(s) : Upacicalcet Sodium

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Launch Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Pathalys Pharma

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Pathalys Pharma

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Upacicalcet Sodium

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Abingworth

                            Deal Size : $150.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Pathalys Pharma Raises $150 Million in Secured Product Financing and Equity led by Abingworth; Forms Strategic...

                            Details : The co-development agreement creates a collaboration that combines the exceptional clinical development resources available through Launch Tx and the extensive dialysis expertise of Pathalys to advance the Upasita (upacicalcet) clinical development progr...

                            Brand Name : Upasita

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 18, 2023

                            Lead Product(s) : Upacicalcet Sodium

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Abingworth

                            Deal Size : $150.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Pathalys Pharma

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Pathalys Pharma

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Upacicalcet Sodium

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pathalys Pharma Announces Phase 3 Program for Upacicalcet

                            Details : The primary endpoint was proportion of patients with mean iPTH between 60 and 240 pg/mL over weeks 22 to 24 and was achieved in 69 of 103 patients (67.0 percent) in upacicalcet group and 4 of 50 patients (8.0 percent) in the placebo group (difference of ...

                            Brand Name : Upasita

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 07, 2022

                            Lead Product(s) : Upacicalcet Sodium

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Pathalys Pharma

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Pathalys Pharma

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Upacicalcet Sodium

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : DaVita Venture Group

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Pathalys Pharma, Inc. Launches with Mission to Address High Priority Needs in Chronic Kidney Disease

                            Details : Pathalys launches with a novel clinical-stage asset, upacicalcet, that was acquired through a license granted by EA Pharma for exclusive rights to the development and commercialization of the product, worldwide outside of Japan and Asia.

                            Brand Name : Upasita

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 01, 2022

                            Lead Product(s) : Upacicalcet Sodium

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : DaVita Venture Group

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sanwa Kagaku Kenkyusho

                            Japan arrow
                            CPhI India 2024
                            Not Confirmed

                            Sanwa Kagaku Kenkyusho

                            Japan arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Upacicalcet Sodium

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Kissei Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Launch of UPASITA® IV Injection Syringe for the Treatment of Secondary Hyperparathyroidism in Dialysis Patien...

                            Details : UPASITA® is administered by intravenous injection to dialysis patients through dialysis circuit and it is possible to adjust the dose and control the medication under the control of physicians or medical staffs.

                            Brand Name : Upasita

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 19, 2021

                            Lead Product(s) : Upacicalcet Sodium

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Kissei Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth